Detalhe da pesquisa
1.
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study.
Lancet
; 403(10427): 632-644, 2024 Feb 17.
Artigo
Inglês
| MEDLINE | ID: mdl-38246194
2.
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.
Lancet
; 397(10272): 375-386, 2021 01 30.
Artigo
Inglês
| MEDLINE | ID: mdl-33485464
3.
OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors.
Clin Cancer Res
; 27(2): 460-472, 2021 01 15.
Artigo
Inglês
| MEDLINE | ID: mdl-33148673
4.
An Integrative Approach to Inform Optimal Administration of OX40 Agonist Antibodies in Patients with Advanced Solid Tumors.
Clin Cancer Res
; 25(22): 6709-6720, 2019 11 15.
Artigo
Inglês
| MEDLINE | ID: mdl-31573956